KBU2046

Overview

KBU2046 is an orally active transforming growth factor-β ( TGF-β1 ) inhibitor. KBU2046 reduces integrin family protein expression, decreases Raf , RIPK1 and ERK phosphorylation to deactivate the ERK signaling pathway, and down-regulates genes linked to TGF-β1 maturation. KBU2046 suppresses tumor cell motility, impedes cancer invasion and metastasis, and inhibits human ESCC growth and metastasis in a murine model. KBU2046 can be used for the researches of triple-negative breast cancer and esophageal squamous cell carcinoma.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Disease Areas > Esophageal Cancer | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > RIP kinase | Products > Signaling Pathways > ERK | Products > Signaling Pathways > TGF-β Receptor | Products > Signaling Pathways > Integrin | Products > Signaling Pathways > Raf

Product Information

• Catalog No.: HY-120548
• CAS No.: 1143863-69-7
• Molecular Formula: C15H11FO2
• Molecular Weight: 242.25
• Purity: 98.85%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution
• Availability: In-stock

Source

Original product source